The evolving TROP2-directed ADC landscape in metastatic NSCLC

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Dr. Farah Louise Lim is a Medical Oncologist at St Bartholomew’s Cancer centre, London, where she leads the lung cancer clinical trials unit.

Her research focuses on novel therapies for early- and late-stage lung cancer, particularly antibody–drug conjugates (ADCs) and bispecific antibodies, alongside the development of biomarkers to guide therapy selection and improve patient outcomes.

Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.

Dr Sands received his MD from the University of Cincinnati in 2005.

He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis.

He joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017 and is the Associate Chief.

His research focuses on improved diagnostics and treatments for lung cancer and is a co-founder and President of the Rescue Lung Society, a non-profit medical society focused on advancing lung screening.

Stephanie McDonald is a Nurse Practitioner in the Thoracic Oncology Program at Dana-Farber Cancer Institute, where she specialises in providing advanced care for patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and other thoracic malignancies. Stephanie works closely with multidisciplinary teams to develop personalised treatment plans, manage side effects, and support patients and their families throughout their cancer journey.

Stephanie is actively involved in research and education, contributing to the evolving landscape of NSCLC and SCLC care. She has presented at national and international conferences, sharing insights on innovative therapies and best practices in thoracic oncology nursing. Her work has been published in esteemed journals such as the Journal of Cancer Research, The Journal of Clinical Oncology, The Oncologist, and Journal of The Advanced Practitioner in Oncology. Most recently, she co-authored a nurse resource guide on Bispecific T Cell Engagers in solid tumors, further highlighting her commitment to advancing oncology nursing knowledge and improving patient outcomes.

Driven by a passion for empowering both her patients and fellow healthcare providers, Stephanie remains at the forefront of NSCLC and SCLC care, blending compassionate nursing practice with evidence-based research and education.

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Dr. Farah Louise Lim is a Medical Oncologist at St Bartholomew’s Cancer centre, London, where she leads the lung cancer clinical trials unit.

Her research focuses on novel therapies for early- and late-stage lung cancer, particularly antibody–drug conjugates (ADCs) and bispecific antibodies, alongside the development of biomarkers to guide therapy selection and improve patient outcomes.

Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.

Dr Sands received his MD from the University of Cincinnati in 2005.

He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis.

He joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017 and is the Associate Chief.

His research focuses on improved diagnostics and treatments for lung cancer and is a co-founder and President of the Rescue Lung Society, a non-profit medical society focused on advancing lung screening.

Stephanie McDonald is a Nurse Practitioner in the Thoracic Oncology Program at Dana-Farber Cancer Institute, where she specialises in providing advanced care for patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and other thoracic malignancies. Stephanie works closely with multidisciplinary teams to develop personalised treatment plans, manage side effects, and support patients and their families throughout their cancer journey.

Stephanie is actively involved in research and education, contributing to the evolving landscape of NSCLC and SCLC care. She has presented at national and international conferences, sharing insights on innovative therapies and best practices in thoracic oncology nursing. Her work has been published in esteemed journals such as the Journal of Cancer Research, The Journal of Clinical Oncology, The Oncologist, and Journal of The Advanced Practitioner in Oncology. Most recently, she co-authored a nurse resource guide on Bispecific T Cell Engagers in solid tumors, further highlighting her commitment to advancing oncology nursing knowledge and improving patient outcomes.

Driven by a passion for empowering both her patients and fellow healthcare providers, Stephanie remains at the forefront of NSCLC and SCLC care, blending compassionate nursing practice with evidence-based research and education.